Back to News
Market Impact: 0.35

$10,000 in Axon Stock a Decade Ago Would Be Worth About $329,000 Today. The Stock Is Down Over the Past Year.

Corporate EarningsCompany FundamentalsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)
$10,000 in Axon Stock a Decade Ago Would Be Worth About $329,000 Today. The Stock Is Down Over the Past Year.

Axon reported Q2 revenue up 35% YoY to $904M (10th straight quarter above 30%) with software up 36% to $398M and connected devices up 35% to $507M. Annual recurring revenue rose 39% to $1.64B and contracted bookings increased 41% to $15.1B, while management lifted its 2026 revenue growth outlook to 32%–34%. Despite the growth, the shares slid after the quarter on valuation/multiple and a small margin slip (adjusted gross margin 62.9% and GAAP net income of $29M vs $155M adjusted), leaving downside risk if growth falls toward ~20%.

Analysis

This is less a change in business quality than a reset in what the market is willing to pay for duration. AXON still has the classic high-visibility software-attach model, but at this valuation the stock is effectively priced as though 30%+ growth is the floor; that makes it fragile to even modest slowing or mix-driven margin pressure. The immediate beneficiaries are AXON's own software economics, but the second-order winner is any lower-multiple public-safety platform vendor, especially Motorola Solutions (MSI), if agencies decide they can get "good enough" functionality without paying a premium multiple for it.

Near term, the market will care more about gross margin trajectory than top-line growth. A small margin slip is meaningful because it suggests newer products and services are still dilutive before scale catches up; if that persists for 1-2 quarters, EPS can lag revenue and the stock can de-rate 20-30% without a true business slowdown. The thesis is falsified if gross margin re-expands back above the low-60s and contract conversion stays strong; otherwise, any procurement delay or evidence of slower booking conversion becomes a catalyst for another leg down.

Contrarian view: consensus is probably over-indexing on the "buy the dip in a compounder" narrative and underweighting how sensitive this setup is to normalization from high-30s growth into the high-20s. Over 6-18 months the business can still compound if bookings convert and free cash flow inflects, but over the next 1-3 months the stock is mostly a multiple trade. In other words, the upside case is intact, but the risk/reward is better lower; patience beats aggression here.

More News